Literature DB >> 22514109

The biology and the genetics of Hurthle cell tumors of the thyroid.

Valdemar Máximo1, Jorge Lima, Hugo Prazeres, Paula Soares, Manuel Sobrinho-Simões.   

Abstract

The biology and the genetics of Hürthle cell tumors are reviewed starting from the characterization and differential diagnosis of the numerous benign and malignant, neoplastic and nonneoplastic lesions of the thyroid in which Hürthle cell transformation is frequently observed. The clinicopathologic and molecular evidence obtained from the comparative study of the aforementioned conditions indicate that Hürthle cell appearance represents a phenotype that is superimposed on the genotypic and conventional histopathologic features of the tumors. Hürthle cell tumors differ from their non-Hürthle counterparts regarding the prevalence of large deletions of mitochondrial DNA (mtDNA), mutations of mtDNA genes coding for oxidative phosphorylation (OXPHOS) proteins (namely mutations of complex I subunit genes) and mutations of nuclear genes coding also for mitochondrial OXPHOS proteins. Such mitochondrial alterations lead to energy production defects in Hürthle cell tumors; the increased proliferation of mitochondria may reflect a compensatory mechanism for such defects and is associated with the overexpression of factors involved in mitochondrial biogenesis. The mitochondrial abnormalities are also thought to play a major role in the predisposition for necrosis instead of apoptosis which seems to be blocked in most Hürthle cell tumors. Finally, the results obtained in experimental models using cybrid cell lines and the data obtained from histopathologic and molecular studies of familial Hürthle cell tumors are used, together with the aforementioned genetic and epigenetic alterations, to progress in the understanding of the mechanisms through which mitochondrial abnormalities may be involved in the different steps of thyroid carcinogenesis, from tumor initiation to metastization.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22514109     DOI: 10.1530/ERC-11-0354

Source DB:  PubMed          Journal:  Endocr Relat Cancer        ISSN: 1351-0088            Impact factor:   5.678


  21 in total

1.  Afirma Gene Sequencing Classifier Compared with Gene Expression Classifier in Indeterminate Thyroid Nodules.

Authors:  Mayumi Endo; Fadi Nabhan; Kyle Porter; Katie Roll; Lawrence A Shirley; Irina Azaryan; Dena Tonkovich; Jeanette Perlick; Laura E Ryan; Raheela Khawaja; Shumei Meng; John E Phay; Matthew D Ringel; Jennifer A Sipos
Journal:  Thyroid       Date:  2019-07-17       Impact factor: 6.568

2.  Thyroid Hürthle cell tumors: research of potential markers of malignancy.

Authors:  G Donatini; A Beaulieu; M Castagnet; J-L Kraimps; P Levillain; G Fromont
Journal:  J Endocrinol Invest       Date:  2015-07-19       Impact factor: 4.256

3.  Phosphorylated Mechanistic Target of Rapamycin (p-mTOR) and Noncoding RNA Expression in Follicular and Hürthle Cell Thyroid Neoplasm.

Authors:  Adam Covach; Sanjay Patel; Heather Hardin; Ricardo V Lloyd
Journal:  Endocr Pathol       Date:  2017-09       Impact factor: 3.943

4.  mTOR Inhibition promotes TTF1-dependent redifferentiation and restores iodine uptake in thyroid carcinoma cell lines.

Authors:  Theo S Plantinga; Bas Heinhuis; Danny Gerrits; Mihai G Netea; Leo A B Joosten; Ad R M M Hermus; Wim J G Oyen; Rebecca E Schweppe; Bryan R Haugen; Otto C Boerman; Johannes W A Smit; Romana T Netea-Maier
Journal:  J Clin Endocrinol Metab       Date:  2014-04-08       Impact factor: 5.958

5.  The oncocytic subtype is genetically distinct from other pancreatic intraductal papillary mucinous neoplasm subtypes.

Authors:  Olca Basturk; Marcus Tan; Umesh Bhanot; Peter Allen; Volkan Adsay; Sasinya N Scott; Ronak Shah; Michael F Berger; Gokce Askan; Esra Dikoglu; Vaidehi Jobanputra; Kazimierz O Wrzeszczynski; Carlie Sigel; Christine Iacobuzio-Donahue; David S Klimstra
Journal:  Mod Pathol       Date:  2016-06-10       Impact factor: 7.842

6.  PTEN and TP53 Mutations in Oncocytic Follicular Carcinoma.

Authors:  Shuanzeng Wei; Virginia A LiVolsi; Kathleen T Montone; Jennifer J D Morrissette; Zubair W Baloch
Journal:  Endocr Pathol       Date:  2015-12       Impact factor: 3.943

7.  METASTATIC HÜRTHLE CELL CARCINOMA PRESENTING WITH LOW FREE THYROXINE, SEVERE HYPERCALCEMIA AND SPURIOUS GROWTH HORMONE PRODUCTION.

Authors:  S Rehman; K K Dhatariya
Journal:  AACE Clin Case Rep       Date:  2019-04-25

8.  Cytological and molecular diagnosis of Hürthle cell thyroid tumors: Analysis of three cases.

Authors:  Sergei E Titov; Tatiana L Poloz; Yulia A Veryaskina; Vladimir V Anishchenko
Journal:  Mol Clin Oncol       Date:  2021-05-28

9.  Multi-parameter systematic strategies for predictive, preventive and personalised medicine in cancer.

Authors:  Rong Hu; Xiaowei Wang; Xianquan Zhan
Journal:  EPMA J       Date:  2013-01-22       Impact factor: 6.543

Review 10.  Inherited Thyroid Tumors With Oncocytic Change.

Authors:  Marcelo Correia; Ana Rita Lima; Rui Batista; Valdemar Máximo; Manuel Sobrinho-Simões
Journal:  Front Endocrinol (Lausanne)       Date:  2021-06-09       Impact factor: 5.555

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.